交银国际发布研报指出，将2024-26年净亏损预测调高至14.8亿/10.4亿/3.4亿元，出于更保守的授权收入及更高的成本费用预测，并将泰它西普和维迪西妥的峰值销售额（含海外）下调至48亿/24亿元。目标价由56港元下调至24港元，维持“买入”评级。Remegen (09995) fell more than 8% again, as of press time, a decrease of 8.42%, at HKD 12.84, with a turnover of 36.8327 million HKD.
According to the Zhitong Finance APP, Remegen (09995) fell more than 8% again, with a decrease of 8.42%, at HKD 12.84, with a turnover of 36.8327 million HKD.
On the news front, Remegen recently released its performance for the first half of the year, with revenue of 0.74 billion RMB, a year-on-year increase of 76.5%; shareholders' attributable losses of 0.78 billion RMB, a year-on-year increase of 10.96%. No interim dividends will be distributed. As of the first half of 2024, Remegen still had 0.673 billion RMB remaining in its accounts, a decrease of nearly 40% year-on-year.
Bocom Intl released a research report stating that the net loss forecast for 2024-2026 has been raised to 1.48 billion/1.04 billion/0.34 billion RMB. This is due to more conservative revenue forecasts and higher cost estimates, as well as a downward revision of peak sales for Taitsip and Vedsitux (including overseas) to 4.8 billion/2.4 billion RMB. The target price has been lowered from HKD 56 to HKD 24, maintaining a 'buy' rating.